Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease
DB Hogan - The Canadian Journal of Psychiatry, 2014 - journals.sagepub.com
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
[HTML][HTML] Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease
DB Hogan - Canadian Journal of Psychiatry. Revue Canadienne …, 2014 - ncbi.nlm.nih.gov
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
DB Hogan - Canadian Journal of psychiatry. Revue Canadienne de …, 2014 - europepmc.org
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease
DB Hogan - … journal of psychiatry. Revue canadienne de …, 2014 - pubmed.ncbi.nlm.nih.gov
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease.
DB Hogan - Canadian Journal of Psychiatry, 2014 - search.ebscohost.com
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEls), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEls), the current mainstay of symptomatic pharmacotherapy for …
[PDF][PDF] Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease
DB Hogan - The Canadian Journal of Psychiatry, 2014 - academia.edu
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease
DB Hogan - Canadian Journal of Psychiatry, 2014 - search.proquest.com
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase Inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase Inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
DB Hogan - Canadian Journal of psychiatry. Revue Canadienne de …, 2014 - europepmc.org
Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …
cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for …